MedTrace Logo

Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study

NCT06988319 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-10-10

No results posted yet for this study

Summary

The primary aim is to determine the feasibility of enrolling and 15 women with chronic pelvic pain (CPP) that have failed one conventional for CPP to obtain preliminary safety data on a single administration of a moderate dose of pharmaceutical grade psilocybin (25 mg) in combination with psychotherapy sessions (two pre-dose preparatory and three post-dose integration sessions).

Conditions

  • Chronic Pelvic Pain

Interventions

DRUG

Psilocybin (Usona Institute)

Single dose of pharmaceutical grade psilocybin (25 mg) combined with psychotherapy sessions

Sponsors & Collaborators

  • Portland Psychotherapy Clinic, Research, and Training Center

    collaborator OTHER

  • Oregon Health and Science University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06988319 on ClinicalTrials.gov